- Home
- NMI vs COYA Comparison
NMI vs COYA Comparison
Compare NMI & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMI
- COYA
- Stock Information
- Founded
- NMI 1988
- COYA 2020
- Country
- NMI United States
- COYA United States
- Employees
- NMI N/A
- COYA N/A
- Industry
- NMI Trusts Except Educational Religious and Charitable
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- NMI Finance
- COYA Health Care
- Exchange
- NMI Nasdaq
- COYA Nasdaq
- Market Cap
- NMI 96.9M
- COYA 98.5M
- IPO Year
- NMI N/A
- COYA 2022
- Fundamental
- Price
- NMI $9.95
- COYA $6.41
- Analyst Decision
- NMI
- COYA Strong Buy
- Analyst Count
- NMI 0
- COYA 4
- Target Price
- NMI N/A
- COYA $16.25
- AVG Volume (30 Days)
- NMI 28.4K
- COYA 92.0K
- Earning Date
- NMI 01-01-0001
- COYA 03-18-2025
- Dividend Yield
- NMI 4.10%
- COYA N/A
- EPS Growth
- NMI N/A
- COYA N/A
- EPS
- NMI N/A
- COYA N/A
- Revenue
- NMI N/A
- COYA $9,554,315.00
- Revenue This Year
- NMI N/A
- COYA N/A
- Revenue Next Year
- NMI N/A
- COYA $56.22
- P/E Ratio
- NMI N/A
- COYA N/A
- Revenue Growth
- NMI N/A
- COYA N/A
- 52 Week Low
- NMI $8.30
- COYA $4.75
- 52 Week High
- NMI $10.05
- COYA $10.69
- Technical
- Relative Strength Index (RSI)
- NMI 65.15
- COYA 52.07
- Support Level
- NMI $9.66
- COYA $5.85
- Resistance Level
- NMI $9.93
- COYA $7.25
- Average True Range (ATR)
- NMI 0.11
- COYA 0.51
- MACD
- NMI 0.01
- COYA -0.04
- Stochastic Oscillator
- NMI 93.55
- COYA 32.94
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.